Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems
Developing therapeutics for inflammatory diseases is challenging due to physiological mucosal barriers, systemic side effects, and the local microbiota. In the search for novel methods to overcome some of these problems, drug delivery systems that improve tissue-targeted drug delivery and modulate t...
Main Authors: | Matteo Puccetti, Marilena Pariano, Paulina Wojtylo, Aurélie Schoubben, Stefano Giovagnoli, Maurizio Ricci |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/2/506 |
Similar Items
-
Pharmaceutically Active Microbial AhR Agonists as Innovative Biodrugs in Inflammation
by: Matteo Puccetti, et al.
Published: (2022-03-01) -
Indole-3-Aldehyde Reduces Inflammatory Responses and Restores Intestinal Epithelial Barrier Function Partially via Aryl Hydrocarbon Receptor (AhR) in Experimental Colitis Models
by: Wang M, et al.
Published: (2023-12-01) -
Indole-3-Carboxaldehyde Restores Gut Mucosal Integrity and Protects from Liver Fibrosis in Murine Sclerosing Cholangitis
by: Fiorella D’Onofrio, et al.
Published: (2021-06-01) -
Dietary AhR Ligands Regulate AhRR Expression in Intestinal Immune Cells and Intestinal Microbiota Composition
by: Oliver Schanz, et al.
Published: (2020-04-01) -
Gut Microbial Catabolites of Tryptophan Are Ligands and Agonists of the Aryl Hydrocarbon Receptor: A Detailed Characterization
by: Barbora Vyhlídalová, et al.
Published: (2020-04-01)